In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

Potential Expansion Into Additional Indications

 
• By Sushmita Panda
  
Clinical research
Promising topline Phase II results for Tourmaline's quarterly IL-6 inhibitor. (Shutterstock)

More from Clinical Trials

More from Therapy Areas